New Hair Loss Medication
About this video
Gillett and James O’Hara review an investigational hair-loss candidate described as targeting scalp stem cells, contrasting it with existing approaches that, they explain, either reduce DHT or stimulate growth. They stress that the available results come from an early-phase trial and amount, in their view, to a teaser rather than proof. Gillett argues headline density gains are hard to interpret without baseline hair counts, warns that follicles with no remaining stem cells cannot be reactivated by this mechanism, and questions whether any early gain will be durable. Their conclusion is cautious interest, not readiness for clinical use, pending larger and longer trials.
Key takeaways
- Judge early-phase hair-loss results as preliminary, not as proof of efficacy
- Percent density gains mean little without knowing the starting baseline
- Gillett theorizes stem-cell approaches need a stem cell still present to work
- Short trials can reflect hair-cycle shifts rather than lasting regrowth
- Wait for later-phase data before comparing a candidate to established treatments
Episode details: published December 12, 2025 · 1.1K views · 14:17 long. Summary written by Self Growth Videos from the episode itself. The hormone, metabolic and peptide concepts described are Dr. Kyle Gillett’s, presented for education — not medical advice. Consult a qualified professional before changing your own health practices. Disclosure: Gillett Health is a clinical practice that treats these conditions.
← Previous: Are GLP1s making us all weak? · Next: Doctor ranks his favorite GLP-1’s →
All Dr. Kyle Gillett videos · Dr. Kyle Gillett profile · Gillett Health (official site)
